We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proton Therapy for Hodgkin Lymphoma (HL01)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00850200
First Posted: February 24, 2009
Last Update Posted: August 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
University of Florida
February 20, 2009
February 24, 2009
December 13, 2013
March 21, 2014
August 23, 2017
August 2009
May 2013   (Final data collection date for primary outcome measure)
Comparison of Normal Tissue Exposed to Greater Than or Equal to 4 Gy/CGE With Use of Proton Therapy Compared to Both Intensity Modulated Radiotherapy (IMRT) and Conventional Therapy. [ Time Frame: Immediately proceeding completion of each of the three treatment plans ]
To assess the reduction of normal tissue exposed to greater than or equal to 4 Gy/CGE with use of proton therapy compared to photon therapy. [ Time Frame: Prior to starting radiation therapy. ]
Complete list of historical versions of study NCT00850200 on ClinicalTrials.gov Archive Site
  • Assess Improvement and Other Dosimetric Endpoints [ Time Frame: Prior to starting radiation therapy ]
  • Assess Disease Control and Survival Outcomes [ Time Frame: During radiation therapy; then after radiation, every 3 months for the first year, then every 6 months for the next 4 years, then annually ]
  • Assess improvement and other dosemetric endpoints [ Time Frame: Prior to radiation therapy ]
  • Collect and analyze morbidity outcomes [ Time Frame: During radiation therapy, every 3 months for the first year, then every 6 months for the next 4 years, then annually ]
  • Assess Disease Control and Survival Outcomes [ Time Frame: During radiation therapy, every 3 months for the first year, then every 6 months for the next 4 years, then annually ]
Not Provided
Not Provided
 
Proton Therapy for Hodgkin Lymphoma
Improving the Therapeutic Ratio by Using Proton Beam Radiation Therapy for Patients With Stage IA-IIIBX (Bulky/Non-bulky) Hodgkin Lymphoma Involving the Mediastinum Following Standard Chemotherapy
The purpose of this study is to reduce the risk of radiation related side effects and complications by treating with radiation (protons or photons) that exposes less of normal organs to low dose radiation.

3 treatment plans will be created to deliver between a total of 21-39.6 Gray (Gy)/Centigray Equivalents (CGE) to the planning target volume (PTV).

  1. Proton Plan
  2. Conventional Plan
  3. Intensity Modulated Radiotherapy (IMRT) Plan

The patient will then receive the radiation modality with the lowest percentage of the body receiving 4 Gy (V4Gy/CGE)

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hodgkin Lymphoma
  • Radiation: Proton Radiation Plan
    Between 21-39.6 Gy/CGE to the PTV
  • Radiation: Conventional Photon Radiation Plan
    Between 21-39.6 Gy/CGE to the PTV
  • Radiation: Intensity Modulated Radiation Plan
    Between 21-39.6 Gy/CGE to the PTV
  • Experimental: Proton Radiation Plan
    Intervention: Radiation: Proton Radiation Plan
  • Active Comparator: Conventional Photon Radiation Plan
    Intervention: Radiation: Conventional Photon Radiation Plan
  • Active Comparator: Intensity Modulated Radiation Plan
    Intervention: Radiation: Intensity Modulated Radiation Plan

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
20
July 2020
May 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed "classic" Hodgkin lymphoma.
  • Completed chemotherapy.

Exclusion Criteria:

  • Prior radiotherapy.
  • Prior or concurrent cancer other than non-melanomatous skin cancer.
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00850200
UFPTI 0806 - HL01
Yes
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
University of Florida
University of Florida
Not Provided
Principal Investigator: Bradford S Hoppe, MD, MPH University of Florida Proton Therapy Institute
University of Florida
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP